Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543362 | 1.00 | CYP2C19 (0.41) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL19295530 | 1.00 | CYP2C19 (0.41) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL3490626 | 1.00 | CYP2C19 (0.41) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL913504 | 0.97 | — | — | |
| SCHEMBL9081638 | 0.97 | — | — | |
| SCHEMBL871716 | 0.97 | — | — | |
| SCHEMBL1543632 | 0.94 | CYP2C19 (0.41) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL2670495 | 0.94 | CYP2C19 (0.41) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL31049605 | 0.84 | CYP2C19 (0.35) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 | |
| SCHEMBL21082026 | 0.82 | APLNR (0.41) | CYP2C19GABRR1CYP2D6CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326652-B1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK SHARP & DOHME (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013090929-A1 | AMINO QUINOLINE DERIVATIVES INHIBITORS OF HCV | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | CYP2C19 583/4885GABRR1 652/4885CYP2D6 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.